Webinar | May 2, 2024
12:00 p.m. – 1:00 p.m. EDT
Register here.

For life sciences companies, reverse merger transactions have become increasingly popular. However, merging into a public life sciences company that has experienced a failed clinical program often raises heightened SEC scrutiny and raises legal considerations. During this session, we will discuss:

  • Structuring alternatives;
  • Recent transactions structured as reverse mergers into public companies;
  • SEC comments in connection with recent reverse mergers;
  • Documentation, process and timeline;
  • New SEC Rule 145a and considerations to avoid shell company status;
  • Accounting for reverse acquisitions under US GAAP;
  • Accompanying PIPE and other financing transactions; and
  • Addressing board and employee matters, anticipating litigation and mitigating liability for the board of the new company.